Abbott Laboratories
Rank #318Capital ReturnABT · NYSE · Healthcare
Abbott Laboratories (ABT) — Rank #318 by gross profitability (GP/assets 0.23) · ROE 12.5% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0000001800 · all metrics point-in-time as of the filing date.
About
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Show moreShow less
It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915.
Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- IL
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- abbott.com
Price History
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
$177.76B
P/E (annual)
27.4
P/S (annual)
4.0
P/B
3.4
P/OCF (annual)
18.6
Shareholder Yield
2.3%
Employees
122,000
Industry
Medical Devices
Exchange
NYSE
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passTerry Smith quality gate
Passes 2/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
10.3%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Dilution drag: 0.0% — per-share value needs a total required return of 10.3% once share-count change is priced in.
vs. own 6-year median revenue growth: 5.1%
priced above its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
5.8%
r = 10% (base)
10.3%
r = 12%
14.1%
Net debt / market cap: 14.4%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.23
Primary signal (Novy-Marx).
8th of 9 SIC 2834 peers
Return on equity
12.5%
Gross margin
56.4%
8th of 9 SIC 2834 peers
Revenue growth (YoY)
5.7%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
0.5%
Revenue CAGR (5Y)
5.1%
Earnings CAGR (3Y)
-2.0%
FCF CAGR (3Y)
-1.8%
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
1.10
7th of 9 SIC 2834 peers (best = lowest)
Current ratio
1.39×
8th of 9 SIC 2834 peers
Quick ratio
0.84×
Net cash
-$25.66B
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$7.39B
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
0.13
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
1.5%
Stock-based comp intensity.
Dividend safety
Composite score
2.8 / 5
Piotroski F-Score
F-Score
6 / 9
Fundamental-strength score (0-9).